MorphoSys

Great Wall of China
Biotech

Biogen inks $850M deal with TJ for China rights antibody

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down.
Will Maddox Apr 20, 2026 10:26am
clock delay wait time alarm

Novartis' $2.9B MorphoSys bet stumbles as safety delays filing

Oct 29, 2024 6:16am
MA

Novartis only wanted pelabresib, but MorphoSys had other ideas

Apr 12, 2024 8:53am
merger MA unit combine consolidate deal

Novartis will pay €2.7B to pick up cancer specialist MorphoSys

Feb 5, 2024 7:06pm
Graphic of three faceless profiles aimed diagonally to the right with two check marks in between them Orange background

Third Rock adds 3 new venture partners, including Karuna’s Paul

Jan 25, 2024 10:35am
MorphoSys

MorphoSys fails secondary in blood cancer trial, sinking stock

Nov 21, 2023 5:52am